Adcock Ingram grows revenue, profit; querying low single exit price increase

JSE-listed pharmaceuticals manufacturer Adcock Ingram has increased its revenue and gross profit by 8% year-on-year for the six-month period ended December 31. Its trading profit also increased by 15% and it declared a 125c a share dividend.